Since the identification and cloning of human histone deacetylases (HDACs) and the rapid
approval of vorinostat (Zolinza®) for the treatment of cutaneous T-cell lymphoma, the field of …

Epigenetics is one of the most promising and expanding fields in the current biomedical
research landscape. Since the inception of epigenetics in the 1940s, the discoveries …

Histone deacetylases (HDACs) are considered to be among the most promising targets in
drug development for cancer therapy, and first-generation histone deacetylase inhibitors …

Acute myeloid leukemia (AML) is a hematological malignancy characterized by uncontrolled
proliferation, differentiation arrest, and accumulation of immature myeloid progenitors …

Histone deacetylases comprise a family of 18 genes, which are grouped into classes I–IV
based on their homology to their respective yeast orthologues. Classes I, II, and IV consist of …

Purpose Epigenetic processes are implicated in cancer causation and progression. The
acetylation status of histones regulates access of transcription factors to DNA and influences …

The initiation and progression of cancer is controlled by both genetic and epigenetic events.
Unlike genetic alterations, which are almost impossible to reverse, epigenetic aberrations …

Medicinal Chemistry of Anticancer Drugs, Second Edition, provides an updated treatment
from the point of view of medicinal chemistry and drug design, focusing on the mechanism of …

Abnormal epigenetic control is a common early event in tumour progression, and aberrant
acetylation in particular has been implicated in tumourigenesis. One of the most promising …

Histone deacetylase (HDAC) inhibitors are an emerging class of therapeutics with potential
as anticancer drugs. The rationale for developing HDAC inhibitors (and other chromatin …